Premium
Postoperative adjuvant irradiation and 5‐fluorouracil for adenocarcinoma of the cecum: A pilot study
Author(s) -
Shehata Wagih M.,
Meyer Richard L.,
Krause Raymond J.,
Jazy Foroogh K.,
Cormier William J.
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19841215)54:12<2850::aid-cncr2820541206>3.0.co;2-y
Subject(s) - medicine , adjuvant , surgery , cecum , incidence (geometry) , adjuvant therapy , adenocarcinoma , fluorouracil , stage (stratigraphy) , gastroenterology , carcinoma , chemotherapy , cancer , paleontology , physics , optics , biology
Twenty‐one patients with adenocarcinoma of the cecum were treated in a pilot study between October, 1972 and June, 1982 by right hemicolectomy and received adjuvant postoperative irradiation (40–45 Gy/4–5 weeks) and 5‐Fluorouracil (5‐FU). There were 15, 4, and 2 patients with Stages (Astler‐Coller) B2, C2, and D, respectively. There was no major morbidity nor mortality attributable to the adjuvant therapy. Patients were followed for a minimum of 15 months. Fifteen patients are alive and disease‐free, with a median survival of 34 months (range, 17–79). There were no significant differences in the median survival or incidence of distant metastases when the adjuvant therapy group was matched by sex, age, and stage of disease with a group of patients treated by right hemicolectomy alone. There was a lower local failure rate in the adjuvant group compared with the surgery‐alone group (5% versus 19%) ( P < 0.2). These data suggest that adjuvant therapy for cecal carcinoma is feasible, safe, and may reduce local failures and possibly improve survival in high‐risk patients. It deserves further investigation so that a definite conclusion may be drawn.